Sunesis Pharmaceuticals, Inc.  

(Public, NASDAQ:SNSS)   Watch this stock  
Find more results for Millennium Pharmaceuticals Inc.�
2.37
+0.04 (1.72%)
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.30 - 2.50
52 week 1.00 - 8.45
Open 2.34
Vol / Avg. 1.01M/820,621.00
Mkt cap 170.00M
P/E     -
Div/yield     -
EPS -0.60
Shares 70.62M
Beta 2.37
Inst. own 75%
Aug 3, 2015
Q2 2015 Sunesis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 12, 2015
Sunesis Pharmaceuticals, Inc. Presentations of VALOR Data - 10:00AM EDT - Add to calendar
May 19, 2015
Sunesis Pharmaceuticals Inc at UBS Global Healthcare Conference
May 5, 2015
Q1 2015 Sunesis Pharmaceuticals Inc Earnings Call - Webcast
May 5, 2015
Q1 2015 Sunesis Pharmaceuticals Inc Earnings Release
Mar 25, 2015
Sunesis Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 12, 2015
Q4 2014 Sunesis Pharmaceuticals Inc Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Sunesis Pharmaceuticals Inc Earnings Release
Mar 10, 2015
Sunesis Pharmaceuticals Inc at ROTH Conference
Mar 3, 2015
Sunesis Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1068.85% -749.95%
Operating margin -1026.82% -785.54%
EBITD margin - -785.04%
Return on average assets -85.59% -101.45%
Return on average equity -239.34% -1128.96%
Employees 39 -
CDP Score - -

Address

Suite 400 395 Oyster Point Boulevard
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company focuses on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anti-cancer quinolone derivative (AQD). Vosaroxin has been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company licensed development and commercialization rights to vosaroxin from Dainippon Sumitomo Pharma Co., Ltd. The Company does not have internal manufacturing capabilities for the production of clinical or commercial quantities of vosaroxin.

Officers and directors

Daniel N. Swisher Jr. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer, Executive Vice President - Corporate Development and Finance
Age: 55
Bio & Compensation  - Reuters
Adam R. Craig M.D, Ph.D. Executive Vice President - Development, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
James W. Young Ph.D. Non-Executive Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Steve R. Carchedi Independent Director
Age: 53
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Helen S. Kim Independent Director
Age: 52
Bio & Compensation  - Reuters